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Abstract More than 20 years after its introduction,
intravascular ultrasound (IVUS) has outlived many
other intracoronary techniques. IVUS was useful to
solve many interventional problems and assisted us in
understanding the dynamics of atherosclerosis. It
serves as an established imaging endpoint in large
progression-regression trial and as an important
workhorse in many catheterization laboratories. Now-
adays, increasingly complex lesions are treated with
drug-eluting stents. The application of IVUS during
suchinterventionscanbeveryuseful.Recently,optical
coherence tomography (OCT), a light-based imaging
technique, has entered the clinical arena. The ‘‘omni-
presence’’ of OCT during scientiﬁc sessions and live
courseswithPCImayraiseinmanythequestion:Does
IVUShaveafutureinthe‘‘eraofOCT’’?Threereview
articles, highlighted by this editorial, demonstrate the
broad spectrum of current IVUS applications and
underline the signiﬁcant role of IVUS during the last
two decades. OCT, the much younger technique, still
has to prove its value. Yet OCT is likely to take over
some of the current indications of IVUS as a research
tool. In addition, OCT is currently gaining clinical
signiﬁcance for stent optimization during complex
interventional procedures. Nevertheless, there is little
doubt that IVUS still has a major role in studies on
coronary atherosclerosis and for guidance of coronary
stenting.Thus,ultrasoundandlight—aretheyfriendor
foe? In fact, bothmethods are good intheir ownrights.
They are complementary rather than competitive.
Moreover, in combination, at least for certain indica-
tions, they could be even better.
Keywords Intravascular ultrasound  Optical
coherence tomography  Coronary atherosclerosis 
Progression-regression  Arterial remodeling 
Vulnerable plaque  Drug-eluting stent 
Biodegradable vascular scaffolds
Abbreviations
IVUS Intravascular ultrasound
RF Radiofrequency
OCT Optical coherence tomography
TCFA Thin-cap ﬁbroatheromas
PCI Percutaneous coronary intervention
DES Drug eluting stent
Introduction
More than twenty years after its introduction, intra-
vascular ultrasound (IVUS) is still alive and has
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have disappeared from the clinical arena. IVUS has
been an ‘‘eye-opener’’ that has helped to solve many
interventional problems and assisted us in under-
standing the dynamics of atherosclerosis, which
involves the entire vascular wall during lesion
development. IVUS not only serves as an established
imaging endpoint in large progression-regression
trials, but is also an important workhorse in many
catheterization laboratories around the globe. Now-
adays, increasingly complex lesions are treated with
drug-eluting stents (DES), and the application of
IVUS during such percutaneous coronary interven-
tions (PCI) can be very useful. Recently, optical
coherence tomography (OCT), a novel light-based
invasive imaging technique, has entered the clinical
arena. The ‘‘omnipresence’’ of OCT during scientiﬁc
sessions, during live courses with PCI, and on the
front pages of renowned cardiology journals may
raise in many the question: Does IVUS—the estab-
lished technique—have a future in the ‘‘era of
OCT’’?
To answer this question and to fully understand the
role of IVUS in the past and at present, it is
worthwhile to make a brief step back in time. The
introduction of gray-scale IVUS in the late 1980s,
stimulated meticulous validation studies [1–5]. Fur-
ther improvement in IVUS image quality and device
miniaturization increased the safety and clinical
applicability of this technique. The addition of the
third dimension and the possibility to acquire images
in an ECG-gated fashion permitted highly reproduc-
ible volumetric measurements of plaque and vessel
dimensions [6–8]. Subsequently, the development of
novel techniques for the analysis of IVUS radiofre-
quency data provided quantitative information on
plaque composition [9–12] that could not be obtained
with conventional gray-scale IVUS [13]. In the
current issue of the journal, Garcia-Garcia et al. [9]
present an interesting overview on the development
of gray-scale IVUS and discuss technical similarities
and differences between the radiofrequency-based
IVUS imaging modalities.
In fact, IVUS allowed for the ﬁrst time a direct
visualization of ‘‘the enemy’’ in vivo by depicting the
burden of atherosclerotic changes in the coronary
vessel wall. The hypothesis of arterial remodeling,
which introduced by Glagov et al. [14] based on their
work in vitro, was proven and extended by IVUS
research in vivo [15–18]. IVUS demonstrated posi-
tive vessel remodeling to be an important feature of
both vulnerable and ruptured coronary plaques [16].
Serial examination of the coronary vessel dimensions
with IVUS permitted the assessment of true vascular
remodeling in vivo [15, 17]. In these serial studies, a
broad spectrum of remodeling behavior was demon-
strated; in particular, lumen size of mildly diseased
left main coronary arteries depended more on the
direction of vessel remodeling than on plaque growth
[15, 17]. Such insight into the dynamic nature of
coronary remodeling has had an impact on how
interventional cardiologists estimate true vessel size
in the context of coronary stenting [19, 20].
In addition, IVUS was instrumental in the under-
standing of the dynamic nature of atherosclerosis
progression-regression [18, 21–24]. For the ﬁrst time,
serial IVUS demonstrated in vivo the direct relation
between serum cholesterol and the progression of
plaque size [22]. Subsequently, large-scale multicen-
ter trials with serial IVUS conﬁrmed the aforemen-
tioned observations, and demonstrated the ability of
statins to stop disease progression and to induce
plaque regression at high doses [18, 21]. Serial IVUS
studies provide established surrogate endpoints; this
allows the testing of novel drugs with smaller study
sample sizes and shorter study durations, which is
likely to expedite the process of drug development
and testing [21]. Moreover, there is evidence that
coronary plaque progression as assessed with serial
IVUS is linked with adverse cardiovascular events
[23, 24]. In the current issue of the journal, Gogas
et al. [18] shed light on various aspects of coronary
remodeling and progression-regression studies with
IVUS.
As brieﬂy mentioned above, radiofrequency-based
(RF) IVUS techniques were developed to character-
ize and quantify coronary plaque composition [9–12].
Both technical details and current insights from RF-
IVUS studies are highlighted in the two review
articles by Gracia-Garcia et al. and Gogas et al.
[9, 18]. For instance, RF-IVUS derived thin-caped
ﬁbroatheromas (TCFA) are thought to be IVUS-
equivalents of vulnerable plaques based on histopa-
thological criteria [18]. Observations from the PROS-
PECT study showed a signiﬁcant association between
non-culprit RF-IVUS derived TCFA, assessed at a
single point in time, and future coronary event risk
[25]. But in fact there is only limited knowledge
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therefore, the treatment of non-obstructive lesions
with RF-IVUS derived features of plaque vulnerabil-
ity is still unclear. Recently, a serial study by Kubo
et al. [26] suggested quite dynamic changes in RF-
IVUS derived plaque phenotypes, which questions
the value of single-point observations of plaque
phenotypes. On the other hand, volumetric assess-
ment of necrotic core volume is highly reproducible
and its reduction may reﬂect plaque stabilization,
making this parameter an interesting target for
pharmacological intervention trials [27].
OCT—the ‘‘new kid on the block’’—provides
coronary imaging in vivo with a high near ﬁeld
resolution, which results in a superior lumen border
detection compared to IVUS. However, OCT has a
limited penetration depth, which is an evident short-
coming for the assessment of total vessel size and
vascular remodeling, and implies the inferiority of
OCT in progression-regression trials compared to
IVUS. Yet in the context of vulnerable plaque detec-
tion, only OCT is able to depict and measure ﬁbrous
caps;thismayhelptoidentifyplaquespronetorupture
[28,29].Ontheotherhand,therelativelyuser-friendly
RF-IVUS analysis method provides quantiﬁcation of
different plaque components (e.g. necrotic core vol-
ume) which are displayed in simpliﬁed color-coded
images. The interpretation of the ‘‘pseudo-micro-
scopic’’ OCT images is more difﬁcult; moreover, the
discrimination between lipidic and calciﬁed plaque
components can be quite challenging as both can have
lowimageintensities[29].Consideringtheadvantages
andlimitationsofIVUSandOCTfortheassessmentof
vulnerableplaques, thecombineduseofRF-IVUSand
OCT may improve its detection as recently suggested
[28, 29].
Also in target lesions of percutaneous coronary
interventions (PCI), careful assessment of plaque
composition may be useful, as a large necrotic
core recently predicted cardiac marker release after
stenting—most likely due to microembolization and/
or induction of a no-reﬂow phenomenon [30]. For that
reason, IVUS assessment before PCI may have the
potential to identify lesions at risk of complications
and may help to tailor interventional procedures
(e.g. use of embolic protection devices and/or direct
stenting) [29, 31].
Conventional grayscale IVUS has already proven
its particular value in the early 1990s. It demonstrated
to the interventional community the shortcomings of
that time and was instrumental in developing the
concept of optimizing stent expansion by use of
balloon catheters with a larger size and higher
inﬂation pressures [32]. In fact, IVUS guidance
helped to improve the acute procedural result which
greatly prevented (sub)acute stent thrombosis—the
main problem in the early days of bare metal stenting
[32, 33]. While various studies suggested that the use
of IVUS can result in larger stent dimensions, less
restenosis, and reduced need for repeat revasculari-
zation procedures, the results of various randomized
multicenter studies were not unequivocal with
regards to the routine use of IVUS guidance
[34, 35]. Nevertheless, many experts agree that IVUS
guidance can be very useful during stenting of
bifurcations, left main stems, long lesions, small
vessels, and in diabetics [20]. Moreover, the forward-
looking IVUS catheter, which is currently under
clinical evaluation, may facilitate the recanalization
of chronic total occlusions of coronary arteries. In
addition, IVUS can be extremely helpful in the
prevention, detection, and management of various
complications such as spiral dissections or stent-
related problems.
The introduction of drug-eluting stents (DES)
during the ﬁrst decade of this century virtually
abolished the need for repeat PCI to treat instent
restenosis. The enthusiasm associated with the early
DES results let us believe that IVUS optimization of
stenting became much less important [36]. Then, the
observation of late and very late stent thromboses in
DES represented a ‘‘wake-up call’’ to carefully study
the mechanisms involved. Therefore, various IVUS
studies were performed and suggested that, besides
other factors, DES underexpansion may be particu-
larly important [37–39]. IVUS insights into the
failure of DES as well as other stent-related issues
are discussed in a review by Brugaletta et al. [40]i n
the present issue of the journal. IVUS guidance of
DES implantation was recently shown to reduce late
stent thrombosis and other major adverse cardiac
events as well as the need for repeat revascularization
[41].
New intracoronary devices, such as bioresorbable
vascular scaffolds (BVS), are made of non-metallic
materials that are classiﬁed by RF-IVUS as being
‘‘calciﬁed and necrotic tissue’’ [42, 43]. Although this
classiﬁcation is obviously incorrect (RF-IVUS is not
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technique may help to track the process of biore-
sorption and integration of biodegradable stent
material into the vessel wall [42–46]. Recent data
suggest that after bioresorption the ‘‘normal’’ struc-
tures of the arterial wall may be partially restored
[42]. In the current issue of the journal, Brugaletta
et al. [40] present an interesting overview of the
IVUS guidance of DES and BVS implantation.
Compared to IVUS, the high-resolution technique
OCT provides more detailed information on stent
struts and their interaction with the vessel wall. OCT
permits, for instance, a more accurate assessment of
stent strut apposition to the vessel wall and allows the
identiﬁcation of even very thin neointimal layers
during follow-up of DES [47, 48]. In addition, as
previously discussed, OCT may complement RF-
IVUS when identifying vulnerable high-risk lesions
before stent implantation [29]. In fact, OCT may also
be an interesting tool to study various mechanistical
concepts in the clinical setting—concepts that can
otherwise only be examined with bench-top research
such as micro-computed tomography [49]. Guidance
of coronary stenting with OCT has recently been
shown to be feasible and safe [46].
However, OCT also has some shortcomings in this
particular setting, such as (1) limited assessment of
true vessel size, (2) suboptimal clearance of blood by
ﬂushing large proximal coronary segments, and
(3) lack of computerized plaque tissue detection
[47, 48]. Moreover, while we (greatly) know how to
interpret IVUS, the enormous amount of detail
depicted by OCT requires considerable effort before
we will be able to make full use of all the information
provided by OCT.
The three review articles, highlighted by this
editorial comment, demonstrate the broad spectrum
of current IVUS applications and underline the
signiﬁcant role of IVUS during the last two decades.
OCT is a much younger technique which still has to
prove its value. Yet OCT is likely to take over some
of the current indications of IVUS as a research tool.
In addition, OCT is currently gaining clinical signif-
icance in the ﬁeld of stent optimization during
complex PCI procedures. Nevertheless, there is little
doubt that IVUS still has a major role in studies on
progression-regression and composition of athero-
sclerotic plaques as well as for guidance of coronary
stenting.
Thus, ultrasound and light—are they friend or
foe? In fact, both methods are good in their own
rights. They are complementary rather than compet-
itive. Moreover, in combination, at least for certain
indications, they could be even better.
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